| Trial ID: | L6311 |
| Source ID: | NCT00530309
|
| Associated Drug: |
Gsk716155 For Injection
|
| Title: |
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GSK716155 for injection|DRUG: Placebo
|
| Outcome Measures: |
Primary: Plasma concentrations and PD parameters over time and at the end of study, Up to Week 9 | Secondary: Other metabolic parameters at the end of study, Up to Week 9
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT
|
| Start Date: |
2007-08-01
|
| Completion Date: |
2008-04-17
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-17
|
| Locations: |
GSK Investigational Site, Fukuoka, 812-0025, Japan|GSK Investigational Site, Tokyo, 130-0004, Japan|GSK Investigational Site, Tokyo, 160-0017, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00530309
|
